Enzolytics Inc. announced the addition of Dr. Kirsten Bischof to its Advisory Board. Dr. Bischof brings the Company her vast experience as a Surgeon and healthcare research professional with an established track record of exceptional performance in healthcare. Dr. Bischof is a well-known Trauma and Critical care specialist.

She has spent her career treating patients in South Africa, where the HIV burden is unprecedented. Her appointment is a significant step as Enzolytics positions itself to strengthen its Artificial Intelligence (A.I.) platform. She will assist Enzolytics in identifying innovative early biomarkers for critical care monitoring and advanced hemodynamic management.

In addition, her skills will be crucial as Enzolytics advances its HIV therapeutic ITV-1 in Africa. Dr. Bischof will guide the Company in further developing its A.I. technology. The A.I. platform drives the Company's drug discovery and development and represents an overall strategy to build a strong Intellectual Property portfolio.

In addition, she has been working with the Company's collaborators in Estonia to develop this platform for assessing the effects of nutrition, genetics, and microbiome on diseases.